| ID | Sequence | Length | GC content |
|---|---|---|---|
| HSALNT0289463 | UCCUAGGCCCGCGGGCUAGAGGCACUUUACCGCCCGGCGGGAGCGCCUC… | 2068 nt | 0.6378 |
| HSALNT0361032 | UCCCGGCGGAGUCCUAGGCCCGCGGGCUAGAGGCACUUUACCGCCCGGC… | 1641 nt | 0.6569 |
| HSALNT0361033 | GGCCCGCGGGCUAGAGGCACUUUACCGCCCGGCGGGAGCGCCUCUCCUC… | 2063 nt | 0.6384 |
| HSALNT0361034 | AUGAGCAAACGAAAGUGGCGCGGAUUUCGGGGCGCCCAGCAGGAGCGAG… | 1867 nt | 0.6422 |
| HSALNT0361035 | AGAGGCACUUUACCGCCCGGCGGGAGCGCCUCUCCUCCGCGUCCCUCGC… | 2838 nt | 0.6237 |
| HSALNT0361036 | AGAGGCACUUUACCGCCCGGCGGGAGCGCCUCUCCUCCGCGUCCCUCGC… | 1982 nt | 0.6443 |
This gene is expressed in antisense to the insulin-like growth factor 2 (IGF2) gene and is imprinted and paternally expressed. It is thought to be non-coding because the putative protein is not conserved and translation is predicted to trigger nonsense mediated decay (NMD). Transcripts from this gene are produced in tumors and may function to suppress cell growth. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2015]
A study in human brain tissue within a 27-hour postmortem period identified the IGF2-AS as a stable reference gene among over 90 candidate lncRNAs, validating its potential for postmortem interval estimation [Li et al. DOI:10.1093/fsr/owad003].